← Back to Search

TAD for Breast Cancer (TAD Trial)

N/A
Waitlist Available
Research Sponsored by UNC Lineberger Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Females of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 30 days after chemotherapy discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method or an intrauterine device that meets <1% failure rate for protection from pregnancy in the product label.
Histologic diagnosis of invasive breast cancer, clinical stage T0-3 N1-3 (maximum three abnormal axillary nodes on ultrasound exam) M0.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up two years
Awards & highlights

TAD Trial Summary

This trial is testing if it's accurate to remove specific lymph nodes in the armpit to treat breast cancer that has spread there. Lymph nodes will be removed after systemic therapy and compared with others from the same region.

Eligible Conditions
  • Breast Cancer

TAD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

TAD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~two years
This trial's timeline: 3 weeks for screening, Varies for treatment, and two years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The false negative rate of TAD
Secondary outcome measures
Nodal pathologic complete response
The percentage of lymph nodes removed with ALND not identified by TAD that harbor residual metastasis
The success rate of preoperative localization with the Savi Scout®

TAD Trial Design

1Treatment groups
Experimental Treatment
Group I: Targeted Axillary DissectionExperimental Treatment1 Intervention
After patients have completed their neoadjuvant systemic therapy, they will have a Savi Scout® electromagnetic reflector placed into the clipped axillary lymph nodes. The surgeon will then use the Savi Scout detector intraoperatively to identify and remove your clipped lymph nodes prior to removing the remainder of the axillary lymph nodes in a surgery called an "axillary dissection".
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TAD
2017
N/A
~110

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor
348 Previous Clinical Trials
88,071 Total Patients Enrolled
49 Trials studying Breast Cancer
27,764 Patients Enrolled for Breast Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases
2017. "Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03281720.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top